A Phase I Study: PET Imaging of Cancer Patients Using [18F] 4-L-Fluoroglutamine (2S,4R)

Lymphoma Clinical Trial

Official title: A Phase I Study: PET Imaging of Cancer Patients Using [18F] 4-L-Fluoroglutamine (2S,4R)

Status Recruiting

Clinical Trial Summary

This is a Phase I study. This study is the first time that a new experimental drug called 18FFluoroglutamine, or F-Glutamine, is being used in people. F-Glutamine is a drug designed to be used with PET scanners that can 'see' where F-Glutamine goes in the body, after its injected. PET scanners are one of the kinds of scanners you normally find in a hospital radiology department. The researchers have found that tumors in animals absorb F-Glutamine. The researchers believe that scans with F-Glutamine might be able to find tumors in patients.

This first in-human study is being done to see how long F-Glutamine lasts in the blood, when it is given to people in tiny amounts by an injection, and to see where F-Glutamine goes in the body. If the results of this trial are good, then the study doctors plan to use F-Glutamine in another trial to see if scans with F-Glutamine are better for finding tumors compared to the standard types of scans that doctors use.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Lymphoma
• Neoplasms
• Solid Malignancy

• NCT number: NCT01697930
• Study type: Interventional
• Source: Memorial Sloan Kettering Cancer Center
• Contact: Mark Dunphy, D.O.
• Phone: 212-639-8131
• Status: Recruiting
• Phase: Phase 1
• Start date: September 2012
• Completion date: September 2025